Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.50 |
| ▸ | DPP4 | P27487 | 4/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382397 | 0.99 | NOD1 (0.54) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29382412 | 0.97 | NOD1 (0.55) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31674332 | 0.96 | NOD1 (0.52) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29376967 | 0.94 | NOD1 (0.53) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL30101988 | 0.92 | FOLH1 (0.60) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31256792 | 0.92 | FOLH1 (0.60) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL30101956 | 0.92 | FOLH1 (0.52) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29843198 | 0.91 | NOD1 (0.56) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29371375 | 0.91 | NOD1 (0.56) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL30555003 | 0.91 | DPP7 (0.55) | NOD1DPP8DPP9DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514939-B2 | Stable radiopharmaceutical compositions and uses thereof | ALPHA-9 ONCOLOGY, INC. (CA) | 2026-01-06 | — | — | US | disclosed |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ALPHA-9 ONCOLOGY INC. (CA) | 2025-08-14 | — | — | US | disclosed |
| US-20220162259-A1 | PEPTIDE COMPLEX AND PRODUCTION METHOD THEREFOR, AND USE OF SAID PEPTIDE COMPLEX | KANEKA CORPORATION (JP) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162259-A1 | PEPTIDE COMPLEX AND PRODUCTION METHOD THEREFOR, AND USE OF SAID PEPTIDE COMPLEX | VIP, FURIN, IAPP | NOD1 602/4885DPP8 126/4885DPP9 416/4885 |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RCN1, RABL6, QPCT | NOD1 4563/4885DPP8 4343/4885DPP9 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.